|Epidemiological input data used in the modela|
|Gender||Cancer sites (ICD 10 code)||Expected number of new cases, irrespective of HPV status||HPV prevalence by site (%)||Expected number of new cases attributable to HPV||Prevalence of HPV 16/18 in HPV-positive cancers (%)||Expected number of new cancer cases attributable to HPV 16/18||Prevalence of HPV 6/11 in HPV-positive warts (%)||Expected number of new cancer cases attributable to HPV 6/11|
|Male||Head and neckb||67,354||14,098||12,707|
|Head and neck||13,448||2,715||2,531|
HPV, human papillomavirus.
aIn total 26 countries were considered in the analysis for incidence estimates, i.e. all European Union countries (except Greece, Hungary, Luxembourg, and Romania). Three countries outside the European Union were included (Iceland, Norway and Switzerland).
bincludes several ICD 10 codes related sites (i.e., tongue, gum of the mouth, floor of the mouth, palate, tonsil, piriform sinus), hypopharynx and larynx sites.
Marty et al.
Marty et al. BMC Cancer 2013 13:10 doi:10.1186/1471-2407-13-10